Ewing Sarcoma New Diagnosis
Ewing Sarcoma New Diagnosis
FAPI-1301: 64Cu-LNTH-1363S in Patients with Sarcoma or Gastrointestinal Tract Cancer (PHANTOM)
- Ages: 18 Years and older
This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity and mass dose) and imaging time window of 64Cu-LNTH-1363S (64Cu Radiolabeled FAPi PET/CT Imaging Agent) and to compare its ima ...More
NRSTS2021: A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma
- Ages: up to 30 Years Old
The study participant has been diagnosed with non-rhabdomyosarcoma (NRSTS). Primary Objectives Intermediate-Risk To estimate the 3-year event-free survival for intermediate-risk patients treated with ifosfamide, doxorubicin, pazopanib, surgery, and maintenance pazopanib, with or without RT. ...More
Single arm evaluation of romiplostim to prevent chemotherapy induced thrombocytopenia in patients with Ewing sarcoma.
- Ages: >1 year old
This is a single-arm, multi-center clinical trial to assess the efficacy of romiplostim as a supportive care measure in patients with a new diagnosis of Ewing sarcoma receiving interval-compressed chemotherapy. Romiplostim-BT-2201: Single arm evaluation of romiplostim to prevent chemotherapy induce ...More
Contact Us
To learn more about available sarcoma clinical trials, contact us at cancer@cchmc.org or 513-636-2799.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.
